The interaction of proliferative and antiproliferative eration: Role of MAP kinase.
remodeling. In animal models (e.g., anti-Thy-1 nephritis) pathogenesis of a number of renal diseases and can be experiand in humans, platelet-derived growth factor (PDGF) mentally induced by the mitogen platelet-derived growth factor plays a major role in the pathogenesis of mesangioproli- (PDGF) . Mitogen-activated protein kinase (MAPK) signaling ferative glomerular disorders [1] . It has been observed plays a key role in mesangial cell proliferation. In the present study we examined whether peroxisome proliferator-activated that PDGF is released during immune injury. If the injury 
play a major role in complement-dependent injury to
The inhibitory effect was blocked by a peroxisome proliferatoractivated receptor element (PPRE) decoy oligonucleotide, inthe mesangium, causing nondamaged mesangial cells to dicating that the observed effect of ciglitazone was via PPAR␥ migrate from the extramesangial region and proliferate, activation. Ciglitazone (1 to 20 mol/L) did not affect extracelgiving rise to a mesangioproliferative nephritis [1-3]. lular signal-regulated protein kinase (ERK) activation but in-The signaling pathway activated in PDGF-stimulated hibited the activation of serum response element (SRE) by mitogenesis in the mitogen-activated protein (MAP) kinase 85 Ϯ 6% (P Ͻ 0.01). This effect was associated with a reduction in c-fos expression (80 Ϯ 9%, P Ͻ 0.01). Ciglitazone (1, 10, pathway involves Ras→Raf→MEK→Erk→Elk-1→SRE→ and 20 mol/L) also inhibited cyclin D1 expression by 37 Ϯ c-fos ( Fig. 1) . Extracellular signal-regulated protein ki-8%, 79 Ϯ 15%, and 87 Ϯ 12%, respectively (P Ͻ 0.001 to nase (ERK) directly activates the transcription factor 0.001), and p21 expression by 45 Ϯ 6% (P Ͻ 0.01), 61 Ϯ 10% ELK-1, which binds to the serum response element (P Ͻ 0.001), and 72 Ϯ 8% (P Ͻ 0.001), respectively. Ciglitazone Thiazolidinedione (TZD) analogs are insulin-sensitizing agents that exert many of their effects as peroxisome  2003 by the International Society of Nephrology
Fig. 1. Effect of ciglitazone on platelet-derived growth factor (PDGF)-mediated activation of the mitogen-activated protein kinase (MAPK).
The signal transduction steps linking the PDGF receptor with extracellular signal-regulated protein kinase (ERK) in mesangial cells is shown in the schematics. PDGF activates ERK by phosphorylation. Once activated, ERK translocates to the nucleus and phosphorylates the transcription factor ELK-1. Phosphorylated ELK-1 and serum response factor (SRF) bind to the serum response element (SRE) on the c-fos promoter, leading to c-fos transcription. c-fos dimerizes with c-jun to form the AP-1 complex, which transactivates target genes such as cyclin D1 and stimulating G1 to S phase progression in the cell cycle. Ciglitazone blocks cell cycle progression by inhibiting SRE and cylin D1 formation.
proliferator-activated receptor gamma (PPAR␥) ligands.
METHODS

PPAR␥ is a member of the nuclear hormone receptor
Cell culture superfamily originally shown to play a critical role in Mouse mesangial cells were obtained from American adipocyte differentiation and glucose homeostasis and Type Culture Collection, Manassas, VA, USA and were has been implicated as a regulator of cellular proliferagrown in Ham's F12 and Dulbecco's modified Eagle's tion and inflammatory responses in the kidney [11] . medium (DMEM) with 5% fetal bovine serum (FBS). PPAR␥ receptors are widely distributed in human and Cells were plated in either 24-well plates or 35 mm plates animal tissue, including rat mesangial cells [12] and proxand grown to ϳ60% confluence. Cells were made quiescent imal tubular cells [13] . The TZD analog troglitazone by serum starving them for 48 hours and then treating with stops the progression of glomerulosclerosis by pre-20 ng/mL of PDGF for 24 hours. In some experiments, venting mesangial cell expansion [14] . cells were pretreated with different concentrations (1 to In the present study we sought to investigate the effect 20 mol/L) of ciglitazone for 4 hours before the addition of ciglitazone, another TZD analog, on mesangial cell of PDGF. Cell viability was measured before and after proliferation in the MAP kinase pathway. In addition, treatment with ciglitazone by 3-[4,5]dimethylthiazol-2,5we investigated the effects of ciglitazone in combination diphenyltetrazolium bromide (MTT). with an ERK inhibitor, PD98059, on cell proliferation.
Measurement of cell proliferation
The results indicate that ciglitazone reduces mesangial cell proliferation by inhibiting pathways downstream of Cell proliferation was measured by an Alamar Blue ERK activation. This inhibitory effect is exerted through (Biosource International, Camarillo, CA, USA) based a PPAR␥-dependent pathway. This is the first report demassay as described by Ahmed et al [15] and deFries and onstrating that concurrent administration of upstream and Mitshuhashi [16] . Mesangial cells were plated at 5.0 ϫ downstream inhibitors of MAP kinase pathway can po-10 4 cells in 24-well plates. After serum starvation for 48 hours the cells were treated with PDGF (20 ng/mL) in tentiate an antiproliferative effect on mesangial cells. the presence or absence of ciglitazone (1 to 20 mol/L) strumentation, Eugene, OR, USA) and imaged with a for 24 hours. Alamar Blue was added to all the wells for setup consisting of a cooled CCD camera (Imago T.I.L.L. 4 hours. The final concentration of the dye in each well Photonics; Applied Scientific Instrumentation) attached was 10%. Proliferation was evaluated by microplate specto an image intensifier (VS4-1845; Videoscope, Washingtroflurometer interfaced to an IBM personal computer ton, DC, USA), an epifluorescent light source (T.I.L.L. (Molecular Devices, Sunnyvale, CA, USA) using excita-Photonics Polychrome IV; T.I.L.L. Photonics GmbH, tion wavelength of 530 nm and emission of 560 nm.
Grä feling, Germany), a 515 nm dichroic beam splitter (Omega Optical, Applied Scientific Instrumentation), Measurement of cell viability and a 535 nm emission filter (20 nm band pass; Omega The effect of ciglitazone on mesangial cell viability Optical). The cells were alternatively excited at 490 and was assayed using the Cell Titer 96 cytotoxicity assay 440 nm and imaged at 10-second intervals. Small regions protocol (Promega, Madison, WI, USA). The Cell Titer of interest (ROIs) in the mesangial cells were chosen in 96 assay is based on the cellular conversion of a tetrazowhich the changes in fluorescent intensity ratio F490/ lium salt into a formazan product, which can be easily F440 were analyzed using TILLvisION v3.1 imaging softdetected at a wavelength of 600 nm. Mesangial cells were ware (T.I.L.L.). In a typical experiment the fluorescent plated in 96-well plates. Twenty-four hours later they intensity ratio measurement contained at least 25 to 30 were serum starved for 48 hours. To minimize serum-ROIs. The changes in pH i were calibrated by high-K mediated proliferation and to prevent cell death, the calibrating solution containing 10 mol/L nigericin admesangial cells were supplemented with 0.5% serumjusted to pHs between 6.5 and 8.0. NHE activity was containing media at the end of 48 hours. Two hours later estimated in terms of both steady-state pH i values and ciglitazone was added to the cells and the control cells the rate of proton efflux. The mesangial cells were acid received dimethyl sulfoxide (DMSO) (vehicle). At the loaded by transient 150-second exposures to 15 mmol/L end of 24 hours, 15 L Promega premixed dye solution NH 4 Cl followed by washout with Na ϩ free buffer. Reinwas added to the cells and incubated at 37ЊC for 4 hours troducing external Na ϩ induced recovery of pH i after in a CO 2 incubator. After 4 hours the 100 L solubilizaacid loading. The rate of pH recovery (␦pH i /min) was tion/stop solution was added and the plate was shaken calculated as the derivative of the exponential fit of pH i for one hour. At the end of the hour the absorbance versus time. was recorded at 600 nm using a plate reader (Bio-Tek Instruments, Winooski, VT, USA).
Transfection of pPPRE(AOx) 3 -Luc and PPAR␥ decoy oligonucleotides Transfection of serum response element (SRE)
PPRE decoy oligonucleotide contained two tandem containing reporter vector repeats of the consensus DR1 (AGGTCAAAGGTCA), Mesangial cells were transiently transfected with 200 ng separated by two nucleotides as follows: GCAGGTCA plasmid containing serum response element with se-AAGGTCATTAGGT CAAAGGTCAGC. The scramcretory alkaline phosphatase reporter gene (SRE-SEAP) bled oligonucleotide used in this study was ATATTG purchased from Clontech (BD Biosciences Clontech, CCGTACCTGACTTAGCCCTAT. The decoy or the Palo Alto, CA, USA). Transfections were performed scrambled oligonucleotide was annealed to its respective using Effectene (Promega) according to the manufacturcomplementary sequence in Tris-ethylenediaminetetraer's instruction. Renilla luciferase plasmid with a thymiacetic acid (EDTA) buffer (pH 7.4). Mesangial cells plated dine kinase promoter (pRL-TK) was used as an internal in 24-well plates were cotransfected with 200 ng of PPAR control and was transfected along with SRE-SEAP.
reporter vector, pPPRE(AOx) 3 -Luc, (kindly donated by SEAP activity was measured using Great EscaPe chemi-Dr. C. Glass and Dr. M. Ricotte), renilla luciferase, and luminescence detection kit (Clontech Laboratories) and decoy or scrambled oligonucleotide. The control cells renormalized to renilla luciferase activity. The results were ceived empty vector. Twenty-four hours after transfecexpressed as relative luminesence units (RLU). tion the cells were stimulated with 10 mol/L of ciglita-Measurement of sodium hydrogen exchanger zone. Eighteen hours later the cells were harvested for (NHE) activity luciferase activity and normalized to renilla luciferase. The results were expressed as relative luminescence units Sodium hydrogen exchanger (NHE) activity was mea-(RLU). sured as described by Lyall et al [17] . Briefly, mesangial
For proliferation experiments cells cultured in 24-well cells were intermittently perfused with Ringer's solution plates were transfected with either 200 nmol/L of either containing 25 mol/L of the pH-sensitive fluoroprobe decoy or scrambled oligonucleotides (Life Technologies, BCECF-AM (Molecular Probes, Eugene, OR, USA) for Invitrogen, Carlsbad, CA, USA) using oligofectamine as 60 minutes. The mesangial cells were visualized through per the manufacturer's instruction. After 4 hours the cells a 40ϫ objective with a Zeiss Axioskop 2 plus upright fluorescence microscope (Zeiss, Applied Scientific In-were treated with 20 ng/mL of PDGF in the presence or 
RESULTS
absence of 10 mol/L ciglitazone. Cell proliferation was
Effect of Ciglitazone on cell proliferation measured using Alamar Blue as previously described.
Treatment of serum starved mesangial cells with PDGF (20 ng/mL) for 24 hours significantly increased Western blot analysis proliferation (↑190 Ϯ 9%, P Ͻ 0.05), measured by the Total mesangial cell proteins were extracted according incorporation of Alamar Blue dye (Fig. 2) . Pretreatment to the method described by Lang et al [18] . Unless menwith ciglitazone, troglitazone, and rosiglitazone for 4 tioned otherwise, 50 g total cell proteins were separated hours significantly inhibited PDGF-induced proliferaby sodium dodecyl sulfate polyacrylamide gel electrotion. The antiproliferative effect of ciglitazone was conphoresis (SDS-PAGE) (8% to 16% gradient gel) and centration-dependent, with 33 Ϯ 8% (P Ͻ 0.05), 58 Ϯ electroblotted to nitrocellulose filters (Millipore, Bed-8% (P Ͻ 0.01), and 67 Ϯ 9% (P Ͻ 0.01) inhibition ford, MA, USA). Membranes were blocked for 1 hour at 1 mol/L, 10 mol/L, and 20 mol/L of ciglitazone, with Tris-buffered saline (TBS) containing 5% nonfat respectively (Fig. 2) . Although ciglitazone is a classic dried milk (Bio-Rad, Hercules, CA, USA) and then incu-TZD, it is less potent than either rosiglitazone or troglitabated with the antibodies to pERK (1:10,000), c-fos zone. The antiproliferative potency of the TZD tested (1:5000), cyclin D (1:5000), p21, and p27 (1:1000) in TBS were as follows: troglitazoneϾrosiglitazoneϾciglitazone. containing 5% nonfat dried milk for 18 hours at 4ЊC.
In animal studies it has been shown that troglitazone The membranes were washed three times with TBS and halts mesangial expansion [14] , and it has been demonincubated with horseradish peroxidase (HRP)-conjugated strated that troglitazone affects NHE and spontaneous secondary antibody (1:10,000) for 2 hours at room temacidosis [19] . Therefore we evaluated the role of ciglitaperature, and then washed three times with TBS conzone on NHE activity in cultured mesangial cells. In the taining 0.05% Tween 20. The blots were reprobed with presence and absence of ciglitazone the NHE activity was mouse monoclonal actin antibody to ensure equal load-0.06 Ϯ .01 and 0.06 Ϯ .02 ␦pH/min, respectively, and this ing. Proteins were visualized using the enhanced chemiluminescence (ECL) detection system (Amersham Phar-difference was not statistically significant ( Fig. 3 ). PDGF by both PPAR␥ activation and its effect on NHE.
To confirm that ciglitazone was not cytotoxic to mesangial cells, cell viability was assessed using MTT, which measures mitochondrial function (Fig. 4 ). Since mitotwofold (P Ͻ 0.05) ( Fig. 5 ). Pretreatment of cells with chondrial respiration is also an indicator of cell growth, 1 to 20 mol/L of ciglitazone had no significant effect the mesangial cells were grown in an optimal serum on ERK phosphorylation, indicating that ciglitazone may concentration of 0.5%. At this concentration mesangial be affecting steps downstream from ERK. cell proliferation was minimal. The data in Figure 3 show that ciglitazone (1 to 20 mol/L) has no effect on cell Effect of ciglitazone on serum response element (SRE) mediated gene expression viability as indicated by equivalent mitochondrial activity in control and ciglitazone-treated mesangial cells.
Since ciglitazone could affect the PDGF-stimulated MAP kinase pathway downstream from ERK activation,
Effect of ciglitazone on ERK phosphorylation
we investigated the effect of ciglitazone on PDGF-induced ERK activation plays a major role in PDGF-induced SRE-mediated gene expression. SRE-mediated gene exproliferation of mesangial cells [21] . Inhibition of cell pression was measured in mesangial cells using SRE reproliferation by ciglitazone raised the possibility that the porter vector SRE-SEAP (Fig. 6 ). An almost fourfold effects of ciglitazone may be mediated via inhibition of increase in SEAP activity was observed with 20 ng/mL ERK phosphorylation. ERK phosphorylation was mea-PDGF. As shown in Figure 6 , pretreatment of cells with sured by Western blot analysis using antibodies specific ciglitazone inhibited PDGF-induced SEAP activity in a to phosphorylated ERK. Treatment of cells with PDGF concentration-dependent manner, suggesting that PDGF attenuates SRE mediated gene expression (↓48 Ϯ 9% (20 ng/mL) for 4 hours increased ERK phosphorylation At the end of 48 hours, serum-free media was replaced with 0.5% P Ͻ 0.05, ↓76 Ϯ 7%, P Ͻ 0.01, and ↓85 Ϯ 6, P Ͻ 0.01 at serum-containing media and the cells were exposed to PDGF (20 ng/ 1 mol/L, 10 mol/L, and 20 mol/L, respectively). mL) in presence or absence of 1, 10, and 20 mol/L ciglitazone (Cig). Ciglitazone was added 4 hours prior to the addition of PDGF. After 24 hours, the cells were lysed in ice and total proteins were extracted. increased c-fos expression by 5.5-fold. As shown in Figure 7 , c-fos expression was dose dependently inhibited in mesangial cells pretreated with 1, 10, and 20 mol/L ated attenuation of c-fos expression we monitored the ciglitazone (↓28 Ϯ 8%, P Ͻ 0.05, ↓66 Ϯ 11%, P Ͻ 0.01and expression of cyclin D1 in mesangial cells. Treatment of ↓80 Ϯ 9% P Ͻ 0.01 by 1, 10, and 20 mol/L ciglitazone, serum starved mesangial cells with PDGF (20 ng/mL) respectively). Taken together with the effects of ciglitafor 24 hours markedly up-regulated the protein levels of zone on SRE reporter activity these results demonstrate cyclin D1 (Fig. 8 ). As shown in Figure 8 , pretreatment that ciglitazone attenuates SRE-mediated c-fos expression.
Effect of ciglitazone on c-fos expression
with ciglitazone for 4 hours significantly inhibited PDGFinduced cyclin D1 expression (↓37 Ϯ 8%, P Ͻ 0.01, ↓79 Ϯ Effect of ciglitazone on cyclin D1 expression 15%, P Ͻ 0.001, and ↓87 Ϯ 12%, P Ͻ 0.001 at 1 mol/L, Expression of cyclin D1 acts in G 1 phase to promote 10 mol/L, and 20 mol/L of ciglitazone, respectively). progression through the cell cycle. Increased expression Effect of ciglitazone on p21 and p27 expression of cyclin D1 is regulated by AP-1, a heterodimeric transcription factor containing c-fos and c-jun proteins [10] .
Expression of cyclin D is also regulated by the cyclin D-dependent kinase (CDK) inhibitor p27 kip1 and p21 Cip1 . To examine the downstream effects of ciglitazone-medi-cyclin D1 [22, 23] . We investigated the effect of ciglitazone on p21 expression after 24-hour PDGF stimulation. As shown in Figure 9B , Western blot analysis showed low levels of p21 expression in quiescent mesangial cells, but PDGF increased p21 expression twofold. The cells treated with 1, 10, and 20 mol/L of ciglitazone significantly decreased PDGF-induced p21 expression by 45 Ϯ 6% (P Ͻ 0.01), 61 Ϯ 10% (P Ͻ 0.001), and 72 Ϯ 8% (P Ͻ 0.001), respectively. Taken together with the effect of ciglitazone on cyclin D1 expression, these results demonstrate that ciglitazone attenuates proliferation by increasing cyclin D1 expression as well as affecting the levels of CDK inhibitor p21 and p27.
Role of PPAR␥ in antiproliferative effect of ciglitazone
PPAR␥ agonists such as ciglitazone and other TZDs can inhibit cell proliferation. However, there are recent reports that the pharmacologic effect of these drugs can be independent of PPAR␥ activation [24] [25] [26] . To determine the mechanism involved in the antiproliferative effect of ciglitazone, mesangial cells were cotransfected with a PPAR reporter vector and PPRE decoy oligonucleotide/scrambled oligonucleotide. PPRE-driven luciferase activity was monitored and normalized to renilla luciferase. Compared to cells transfected with vector (Fig. 10A ). 0.5% serum-containing media and the cells were exposed to PDGF (20 To examine the effects of the PPRE decoy on mesanng/mL) in presence or absence of 1, 10, and 20 mol/L of ciglitazone gial cell proliferation, the cells were transiently transfected (Cig) . Ciglitazone was added 4 hours prior to the addition of PDGF. After 24 hours, the cells were lysed in ice and total proteins were with the PPRE decoy/scrambled oligonucleotide and stimuextracted. Total cell extracts (50 g protein) were separated by sodium lated with PDGF. The rationale for this experiment was dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in that the decoy oligonucleotide would bind to the ligand 8-16% gels. Cyclin D1 protein levels were analyzed by immunoblotting using cyclin D1 antibody (1:5000). Actin was used as loading control.
ciglitazone-activated PPAR␥ and prevent PPAR-mediated
The autoradiogram at the top is representative of 5 experiments. Cyclin effects on gene transcription and proliferation. As shown D1 expression was analyzed by scanning the autoradiograms. The ratio in Figure 10B , when the cells were transiently transfected of cyclin D1 and actin was expressed as fold change from the control.
with PPRE decoy oligonucleotide, 10 mol/L of ciglita-The control value was considered to be 100%. The results are expressed as mean Ϯ SD. *P Ͻ 0.01 and ‡P Ͻ 0.001 less than PDGF. zone had no effect on PDGF-induced proliferation. In contrast, when cells were transfected with scrambled oligonucleotide, 10 mol/L of ciglitazone significantly in-Down-regulation of p27 in response to mitogens (e.g., hibited (P Ͻ 0.05) PDGF-stimulated proliferation (Fig.  PDGF) is important for maximal activation of cyclin/ 10B). As shown in Figure 10A , there is a 90% reduction cyclin D kinase holenzyme. We therefore investigated in PPRE-mediated gene expression by decoy, which is the effect of PPAR␥ ligand ciglitazone on p27 protein consistent with the effect of decoy oligonucleotide on cell expression by Western blot analysis. Quiescent mesanproliferation. These observations indicate that ciglitazone gial cells revealed substantial p27 protein expression.
inhibits proliferation via PPAR␥. However, the expression of p27 was attenuated to 33 Ϯ 6% of control (P Ͻ 0.001) after 24 hours exposure of Potentiating effect of ciglitazone and the MEK PDGF. The PDGF-mediated down-regulation of p27 inhibitor, PD98059 was significantly reversed by ciglitazone. The expression PD98059 is a specific inhibitor of ERK activation and of p27 was up-regulated to 56 Ϯ 7% (P Ͻ 0.01), 98 Ϯ has been shown to reduce PDGF-induced ERK activa-17%, and 115 Ϯ 11% (P Ͻ 0.001) of the control by 1, tion in a dose-dependent fashion [27] . Our results dem-10, and 20 mol/L ciglitazone, respectively (Fig. 9A) . In onstrated attenuation of proliferation by ciglitazone and contrast to p27, mitogens are known to up-regulate p21, at a site(s) downstream of ERK activation. Therefore and the expression of p21 protein is required for facilitating functional kinase complex formation of CDK4 and we extended these studies to investigate the combined Fig. 9 . Effect of ciglitazone on plateletderived growth factor (PDGF)-mediated expression of p27 and p21. Mesangial cells were grown (ϳ50% confluence) in 60 mm dishes and made quiescent by 48 hours of serum starvation. Serum-free media was replaced with 0.5% serum-containing media after 48 hours and the cells were exposed to PDGF (20 ng/ mL) in presence or absence of 1, 10, and 20 mol/L of ciglitazone (Cig). Ciglitazone was added 4 hours prior to the addition of PDGF. After 24 hours, the cells were scraped and protein extracts (100 g protein for p21 and 50 g protein for p27) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in 8-16% gels. The blots were analyzed by immunoblotting using p21 antibody (see Fig. 8 ) and p27 antibody (see Fig. 8 ). Actin was used as loading control. The ratio of p21 and actin ( Fig. 8 ) and p27 and actin were expressed as fold change from the control. The control value was considered to be 100%. The results are expressed as mean Ϯ SD.
effects of ciglitazone and PD98059 on PDGF-induced and inhibition of cell growth occurs by blocking the MAP cell proliferation. Pretreatment of cells with threshold kinase pathway at a point downstream from extracellular concentrations of PD98059 (2.5 mol/L) had no signifisignal-regulated protein kinase (ERK) activation (Fig. 1) . cant effect on proliferation. However, the effect of these The ERK pathway is an integral part of the MAP kinase inhibitors in combination was potentiating. As shown in pathway and is critical to the mitogenic response, cellular Figure 11 , PD989059 (2.5 mol/L) further potentiated differentiation, or hypertrophy. Antisense RNA and the inhibitory effect of ciglitazone (1 and 10 mol/L) by dominant-negative mutant studies have clearly docu-34 Ϯ 6% and 50 Ϯ 7%, respectively. Although PD98059 mented that ERK1/2 is essential for cell cycle progression potentiated the antiproliferative effect of ciglitazone [28] . PDGF is responsible for the transduction of mito-(P Ͻ 0.05), the decrease was 50 Ϯ 5% and the percent of genic signals from the cell membrane to the nucleus, change was not significantly different from that observed which involves a cascade of protein-binding events and with 10 mol/L of ciglitazone. These results provide evimodifications, including a series of phosphorylation redence that inhibiting MAPK at proximal (by PD98059mediated inhibition of ERK activation) and distal sites sulting in the activation of MAP kinase pathway. In (by ciglitazone-mediated effect on c-fos, cyclin, p21, and our study ciglitazone did not inhibit phosphorylation of p27) can produce significantly higher antiproliferative ERK, a finding similar to the observation that Ang IIresponse than targeting a single site.
induced ERK activation could not be blocked by TZDs [29] . The ability of ciglitazone alone to inhibit prolifera-DISCUSSION tion indicates that ciglitazone inhibits MAP kinase distal to ERK activation. The present investigation demonstrates that the antiproliferative effect of ciglitazone is mediated by PPAR␥ The ability of PDGF to trigger cell cycle progression response elements in the promoter region [14] and is thus a potential target gene for AP-1 complexes. During depends on c-fos and related transcription factors cell cycle, cyclin D, along with its catalytic partner, CDK, [30, 31] . The cis acting serum response element (SRE) are induced by mitogenic signals. Cip/Kip proteins p21 is crucial for mitogen-induced c-fos transcription. Tranand p27 control cell cycle progression by modulating scriptional activation of the c-fos gene by PDGF is stimucyclin D and CDK binding [22, 23] . Increased expression lated, at least in part, through the interaction of transcripof c-fos leads to activation of cyclin D1, a key mediator tion factors with a SRE located in the c-fos 5Ј-flanking in cell proliferation. Cyclin D1 protein regulates the cell DNA [7, 8] . In our experiments we have shown ciglitacycle by binding to CDK, thereby causing phosphorylazone decreased SRE mediated gene expression. Since tion and inactivation of retinoblastoma tumor suppressor SRE is responsible for transcriptional activation of c-fos, protein, which inhibits G1 to S phase transition. The it was hypothesized that ciglitazone-mediated PPAR␥ promoter for cyclin D1 contains an AP-1 site, and expresactivation will decrease c-fos formation. Our results consion of either c-fos or c-jun induces cyclin D1 mRNA firm the earlier observations of Law et al [32] , who expression [10, 33] . Fibroblasts derived from fosBϪ/Ϫ showed that the TZD analog troglitazone inhibits SRE c-fosϪ/Ϫ mice were found to have a defect in proliferafunction and reduces c-fos mRNA induction by basic tion that results, at least in part, from a failure to induce FGF. cyclin D1 following serum-stimulated cell cycle reentry [34] . Ciglitazone-mediated inhibition c-fos and de-C-fos and its heterodimeric partner c-jun (AP-1 complex) promote cell proliferation by transactivation of creased cyclin D1 expression shown here can result in the blockade of cell proliferation. Compared to SRE cyclin D1, a key protein promoting the cell cycle [9] . Cyclin D1 gene has been shown to harbor two AP-1 and c-fos, equivalent molar concentrations of ciglitazone were more potent in inhibiting cyclin D1 formation, sug-inference, other studies have shown that TZDs play an important role in cell cycle regulation via PPAR␥ [11] . gesting ciglitazone might affect other pathways responsible for the generation of cyclin. Since PPAR␥ agonists Stimulation of the MAP kinase is sufficient to promote cell proliferation [39] . Blockade of the ERK pathway by such as thiazolidinediones can cause substantial blockade of retinoblastoma protein phosphorylation by attenuat-treatment with the MEK inhibitor, PD 98059, suppressed the proliferation of both HT1080 and RPMI-SE tumor ing degradation of CDK inhibitors [35] , the role of ciglitazone on CDK inhibitors was evaluated. Although it is cell lines [40] . In our study PD 98059 significantly augmented the antiproliferative effect of ciglitazone. This generally assumed that CDK inhibitors act solely to retard G 1 progression, the fact that they can be found in interaction between MEK inhibitor and ciglitazone might have therapeutic implications since the combina-complexes with active cyclin CDKs raises the possibility of that they may be positive regulators [22, 23] . In our tion of agents acting at different steps in the MAP kinase signaling pathway might prove to be more effective than experiments PDGF induced the expression of CDK inhibitor p21, and this was blocked by ciglitazone. In-single agents in treating proliferative glomerular disease. creased expression of p21 during proliferation is observed because it acts as a scaffold to facilitate the CONCLUSION assembly of cyclins and CDKs required for DNA synthe-
We have demonstrated that the antiproliferative acsis [23] . It has been shown that PPAR␥ agonist troglitation of ciglitazone is mediated via PPAR␥. This inhibizone blocks glomerular cell proliferation and this effect tion can be enhanced by simultaneous attenuation of is associated with a decrease in p21 expression [14] . Re-ERK phosphorylation by inhibition of pathways upducing the levels of p27 by transfecting mesangial cells stream from ERK (e.g., MEK). Ciglitazone inhibits meswith p27 antisense oligodeoxynucleotides results in an angial cell proliferation by inhibiting SRE-mediated increased magnitude of mesangial cell proliferation intranscriptional activation of c-fos gene, resulting in deduced by PDGF [36] . Our data shows that PDGF downcreased c-fos and cyclin D1 protein expression. Although regulates p27 and the effect is reversed by ciglitazone.
our results further demonstrate that ciglitazone reverses Therefore up-regulation of p27 and down-regulation of the effects of PDGF on p27 and p21 expression, the net p21 by ciglitazone can be a downstream mechanism by result of these changes on CDK activity are currently which PPAR␥ agonist ciglitazone exerts its antiproliferaunder investigation. Furthermore, the potentiating effect tive effect.
of ciglitazone and MEK inhibitor PD 98059 at relatively Antiproliferative effects of TZDs are mediated via lower concentrations on PDGF-induced cell prolifera-PPAR␥ [11, 35] . However, there is a growing body of tion suggest that a significantly higher antiproliferative literature which suggests that TZDs may produce their effect can be achieved by combining two agents acting pharmacologic effect independent of PPAR␥ [24] [25] [26] . In at two different sites in the MAP kinase pathway. a recent study of mouse embryonic stem cells it has been shown that the antiproliferative action of TZDs is the Reprint requests to Anton C. Schoolwerth, Division of Nephrology, consequence of partial depletion of intracellular calcium MCV Campus, Virginia Commonwealth University, Box 980160, Richmond, VA 23298. stores and not by PPAR␥ [24] . To provide the evidence E-mail: aschoolw@mail2.vcu.edu that PPAR␥ is required for the antiproliferative effect of ciglitazone, we developed a double-stranded decoy REFERENCES olignucleotide that corresponds to the PPAR response 1. Cybulsky AV: Growth factor pathways in proliferative glomeruloelement. The rationale for this approach is that the decoy 
